REXULTI BREXPIPRAZOLE - Otsuka Pharmaceutical Co., Inc. Trademark Registration
Por um escritor misterioso
Descrição
Trademark registration by Otsuka Pharmaceutical Co., Inc. for the trademark REXULTI BREXPIPRAZOLE.
Apply for your patients Otsuka Patient Assistance Foundation
Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder
Express Pharma (Vol.10, No.20) August 16-31, 2015 by Indian Express - Issuu
Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
REXULTI BREXPIPRAZOLE - Otsuka Pharmaceutical Co., Ltd. Trademark Registration
REXULTI BREXPIPRAZOLE Trademark of OTSUKA PHARMACEUTICAL CO., LTD. - Registration Number 5052422 - Serial Number 86662242 :: Justia Trademarks
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
Apply for your patients Otsuka Patient Assistance Foundation
Otsuka America Pharmaceutical, Inc. Device Database
ex9901_img004.jpg
Otsuka Patient Assistance Foundation
Otsuka US
Year in Review: Bipolar Disorder and Schizophrenia
Articles about Otsuka Pharmaceutical Co., Ltd.
Rexulti Approved by FDA for Major Depressive Disorder and Schizophrenia
de
por adulto (o preço varia de acordo com o tamanho do grupo)
